ABVC BioPharma, Inc. (ABVC) Return on equity 2020–2025
ABVC BioPharma, Inc. (ABVC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-71.2%FY2025 · since FY2020: -308.1% → -71.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -71.2% | +328.7 pp |
| FY2024 | -399.9% | +101.3 pp |
| FY2023 | -501.1% | +28.9 pp |
| FY2022 | -530.0% | -384.8 pp |
| FY2021 | -145.2% | +162.9 pp |
| FY2020 | -308.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ABVC financial trends
ABVC RevenueABVC Net incomeABVC Net marginABVC Gross profitABVC Gross marginABVC Operating incomeABVC Operating marginABVC Operating cash flowABVC Free cash flowABVC Capital expendituresABVC Stock buybacksABVC Dividends paidABVC Total assetsABVC Total liabilitiesABVC Shareholders’ equityABVC overview →